Early VItrectomy in DENse Spontaneous Vitreous HEmorrhage
NCT ID: NCT04676256
Last Updated: 2024-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
126 participants
INTERVENTIONAL
2021-07-02
2025-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypothesis is that an early vitrectomy could decrease the rate of retinal detachment occurring after a spontaneous vitreous hemorrhage.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitreous Detachment and Glaucoma Progression
NCT04719871
The Role of Intravitreal Glucose in Macular Thinning Following Surgery for Retinal Detachment or Epimacular Membrane
NCT02210481
Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment
NCT06347302
Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy
NCT00155454
Partial Posterior Hyaloidectomy in Macular Surgery
NCT01454466
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The hypothesis is that an early vitrectomy could decrease the rate of retinal detachment occurring after a spontaneous vitreous hemorrhage.
Scientific background Spontaneous vitreous hemorrhage may occur after spontaneous posterior vitreous detachment and causes retinal break and retinal detachment in about 70% and 40% of cases respectively. The fundus examination and ultrasound have limited sensitivity to detect retinal breaks in these cases. Some retrospective studies have highlighted the benefit of an early vitrectomy for decreasing the rate of visual loss due to retinal detachment in these cases. However, to date, there is no national or international consensus regarding the management of spontaneous vitreous hemorrhage and the timing of vitrectomy.
Study design Prospective randomized clinical trial Primary objective To compare the results of an early vitrectomy versus ultrasound and fundus observation in spontaneous vitreous hemorrhage.
Secondary objectives To evaluate the rate of retinal complications in spontaneous vitreous hemorrhage treated either with early or delayed vitrectomy.
To evaluate the rate of visual loss in spontaneous vitreous hemorrhage treated either with early or delayed vitrectomy.
Primary criteria Rate of retinal detachment in eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Secondary criteria Rate of retinal breaks and vitreo-retinal proliferation in eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Visual acuity and rate of eyes with a loss of 5 letters or more among eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Participants Patients with a spontaneous vitreous hemorrhage secondary to posterior vitreous detachment, with a reduced visibility of the fundus Inclusion criteria
* Age \> or = 18 years old
* Spontaneous vitreous hemorrhage which is 1/ secondary to posterior vitreous detachment; 2/ acute: which duration is \< 15 days, 3/ dense: reduced visibility of the fundus
Exclusion criteria:
* Retinal detachment at the initial examination
* Any history of vascular retinal disease (diabetic retinopathy, retinal vein occlusion…)
* Any history of uveitis, age-related macular degeneration
* History of a recent ocular traumatism (\< 3 months)
* History of a recent retinal laser treatment (\< 3 months) or vitreo-retinal surgery (\< 3 months)
* Absence of consent Experimental group Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63) Active Comparator group Eyes with spontaneous vitreous hemorrhage only observed using fundus examination and B-ultrasound (n = 63) Study duration Inclusion: 12 months Participation: 6 months Total duration: 18 months
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early Vitrectomy
Experimental arm will be treated with early vitrectomy early vitrectomy 7 days after vitreous hemorrhage diagnosis
Early vitrectomy
Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
Comparator
Active comparator arm will have fundus and ultrasound observation. Late vitrectomy may be indicated after 3 months of follow-up if needed.
Late vitrectomy will be performed in case of persistant vitreous hemorrhage after 3 months of folllow-up
Early vitrectomy
Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Early vitrectomy
Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Spontaneous vitreous hemorrhage which is :
1. secondary to posterior vitreous detachment;
2. acute: which duration is \< 15 days,
3. dense: reduced visibility of the fundus
Exclusion Criteria
* Any history of vascular retinal disease (diabetic retinopathy, retinal vein occlusion…)
* Any history of uveitis, age-related macular degeneration
* History of a recent ocular traumatism (\< 3 months)
* History of a recent retinal laser treatment (\< 3 months) or vitreo-retinal surgery (\< 3 months)
* Absence of oral and written consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Lariboisiere
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDRCB
Identifier Type: OTHER
Identifier Source: secondary_id
P170408J
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.